Future Warrants Sample Clauses

Future Warrants. In the event the Maximum Credit Limit (as defined above) increases, Borrower agrees that it shall issue to Silicon additional warrants to purchase stock of Borrower, on Silicon’s standard form with such modifications as are acceptable to Silicon in its sole discretion, for an amount of shares equal to 3% of the increase in the Maximum Credit Limit divided by the initial exercise price of such warrant. The class of stock and initial exercise price shall be determined at or about the time of such proposed increase in the Maximum Credit Limit.
Sample 1Sample 2
AutoNDA by SimpleDocs
Future Warrants. With respect to any warrant issued to the BDC and transferred to the Borrower pursuant to the Transaction Document, such warrant shall either be re-issued in the name of the Borrower or a warrant assignment agreement, in such form agreed to by the Borrower and the Agent, shall have been executed by the related Obligor, the BDC and the Borrower and shall, if such warrant is in bearer form, be affixed to such warrant.
Sample 1
Future Warrants. In the event the Maximum Credit Limit is increased, Borrower shall provide Silicon with additional five-year warrants to purchase Common Stock of the Borrower at an exercise price equal to the average closing stock price of Borrower’s Common Stock during the 30 days immediately preceding the date such increase in the Maximum Credit Limit takes effect (the "New Warrant Exercise Price"). The amount of additional Common Stock provided for in such additional warrant(s) shall be equal to 3% of the increase in the Maximum Credit Limit (i.e., (3% x Increase in the Maximum Credit Limit) / New Warrant Exercise Price). Borrower: ENTRADA NETWORKS, INC. By_/s/_Kanwar X. X. Xxxxxx President or Vice President By_/s/ Xxxxxxx Xxxxxxxx Secretary or Ass't Secretary Silicon: SILICON VALLEY BANK By__/s/ Milad Hanna____________ Title__Sr. Vice President________ Borrower: ENTRADA NETWORKS-AJ, INC. By_/s/_Kanwar X. X. Xxxxxx President or Vice President By_/s/ Xxxxxxx Xxxxxxxx Secretary or Ass't Secretary --
Sample 1
Future Warrants. Bank will not issue stock purchase warrants, options or the like for shares of Bank's common stock except as expressly permitted in this Agreement, including without limitation Paragraph E of the "Background" Section of this Agreement. If Bank conducts an offering (other than the Initial Offering) of shares of Bank's common stock that is managed and sold exclusively through the efforts of the officers and directors of Bank and without the involvement in any manner of an underwriter or broker, Bank may issue stock purchase warrants with respect to shares of its common stock to such officers and directors, in an aggregate amount not exceeding 10% of the number of shares sold in such offering. Bank may also from time to time issue additional warrants, options or the like with respect to Bank's common stock to officers or employees of Bank in a reasonable amount, but only with the prior approval of National Penn, which approval will not be unreasonably withheld. Any warrants issued by Bank pursuant to the preceding two sentences shall have a term not in excess of seven years, an exercise price per share of not less than the fair market value of Bank's common stock at the time of issuance, and such other terms and conditions as shall be contained in the stock purchase warrants issuable by Bank in connection with the Initial Offering. The provisions of this Paragraph 11 shall expire automatically and this Paragraph 11 shall be of no further force and effect on the tenth anniversary of the date of this Agreement.
Sample 1

Related to Future Warrants

  • Purchase Warrants The Company hereby agrees to issue and sell to the Representatives (and/or their designees) on the Closing Date option (“Representatives’ Warrants”) for the purchase of an aggregate of [●] shares of Common Stock, representing 5% of the Firm Shares (excluding the Option Shares), for an aggregate purchase price of $100.00. The Representatives’ Warrant agreement, in the form attached hereto as Exhibit A (the “Representatives’ Warrant Agreement”), shall be exercisable, in whole or in part, commencing on a date which is one (1) year after the Effective Date and expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $[●], which is equal to 120% of the initial public offering price of the Firm Shares. The Representatives’ Warrant Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the “Representatives’ Securities.” The Representatives understand and agree that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representatives’ Warrant Agreement and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representatives’ Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter or a selected dealer in connection with the Offering, or (ii) a bona fide officer or partner of the Representatives or of any such Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.

  • Stock Warrants Subject to Board approval, Executive shall be granted stock warrants (the "Two Million Warrants") to purchase an aggregate of Two Million (2,000,000) shares of common stock of the Company. The Two Million Warrants are deemed to be of record as of January 1, 2007. The Two Million Warrants shall be granted in accordance with, and subject to the following:

  • Issue Warrants Issue warrants for Borrower’s capital stock.

  • Exercise of Purchase Warrants Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

  • Forward Purchase Warrants The Forward Purchase Warrants shall have the same terms and be in the same form as the Public Warrants.

  • Private Placement Warrants; Forward Purchase Warrants 2.6.1 The Private Placement Warrants shall be identical to the Public Warrants, except that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below), the Private Placement Warrants: (i) may be exercised for cash or on a “cashless basis,” pursuant to subsection 3.3.1(c) hereof, (ii) including the Ordinary Shares issuable upon exercise of the Private Placement Warrants, may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of an initial Business Combination, (iii) shall not be redeemable by the Company pursuant to Section 6.1 hereof and (iv) shall only be redeemable by the Company pursuant to Section 6.2 if the Reference Value (as defined below) is less than $18.00 per share (subject to adjustment in compliance with Section 4 hereof); provided, however, that in the case of (ii), the Private Placement Warrants and any Ordinary Shares issued upon exercise of the Private Placement Warrants may be transferred by the holders thereof:

  • Purchase Warrant THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of _________ (“Holder”), as registered owner of this Purchase Warrant, to Aytu BioScience, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time from [________________] [DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, [____________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING] (the ”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [____] shares of common stock of the Company, par value $0.0001 per share (the “Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at $[___] per Share [125% of the price of the Shares sold in the Offering]; provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context.

  • The Warrants The Warrants shall have the terms and conditions and be in the form attached hereto as Exhibit B.

  • Private Warrants On the Closing Date and the Option Closing Date, as applicable, the Private Warrants have been purchased as provided for in the Subscription Agreements and the purchase price for such securities shall be deposited into the Trust Account.

  • Ordinary Shares Issuable Upon Exercise of Warrants The Ordinary Shares issuable upon exercise of the Warrants included in the Units and the Private Placement Warrants have been duly authorized and reserved for issuance upon exercise thereof and, when issued and delivered against payment therefor pursuant to the Warrants and the Private Placement Warrants, as applicable, and the Warrant Agreement and registered in the Company’s register of members, will be validly issued, fully paid and non-assessable. The holders of such Ordinary Shares are not and will not be subject to personal liability by reason of being such holders; such Ordinary Shares are not and will not be subject to any preemptive or other similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of such Ordinary Shares (other than such execution (if applicable), countersignature (if applicable) and delivery at the time of issuance) has been duly and validly taken.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!